Immunology and Microbiology
Vaccine Efficacy
99%
Human Respiratory Syncytial Virus
78%
Severe Acute Respiratory Syndrome Coronavirus 2
66%
Human Metapneumovirus
54%
Immune Response
50%
T Cell
35%
Mouse
34%
Vaccination Policy
28%
Humoral Immunity
25%
Immunogenicity
23%
Adoptive Immunity
22%
Infectious Agent
22%
Bacilli
21%
Respiratory Syncytial Virus Infection
21%
Immunocompetent Cell
19%
Neutralizing Antibody
19%
Systemic Lupus Erythematosus
19%
Omicron Coronavirus Variant
18%
Monospecific Antibody
17%
COVID-19
17%
Secretion (Process)
17%
interferon
15%
Surface Property
14%
Viral Disease
13%
Inactivated Vaccine
13%
Adaptive Immune System
13%
Booster Dose
12%
Autoimmunity
12%
Central Nervous System
12%
Mycobacterium bovis
12%
Streptococcus Agalactiae
12%
BCG Vaccine
12%
Interleukin 10
12%
Mycobacterium Bovis BCG
11%
Nucleoprotein
11%
Immune System
10%
Cytokine
9%
Lower Respiratory Tract
9%
Viral Clearance
9%
Neutrophil Granulocyte
8%
Mouse Model
8%
Dendritic Cell
7%
Monocyte
7%
Autoimmune Disease
7%
T-Helper Cell
7%
Inflammatory Arthritis
7%
Blood Plasma
7%
Streptococcus Pneumoniae
6%
Innate Immune System
6%
Normal Human
6%
Keyphrases
Human Respiratory Syncytial Virus (hRSV)
100%
Human Metapneumovirus (hMPV)
54%
Virus
46%
Immune Response
43%
CoronaVac
42%
Respiratory Syncytial Virus Infection
40%
COVID-19
34%
Chile
24%
Vaccination
24%
Neutralizing Antibodies
22%
T Cells
21%
Immunogenicity
19%
Immunization
19%
Severe Acute Respiratory Syndrome coronavirus-2 Vaccine
18%
Respiratory Syncytial Virus
18%
Inactivated SARS-CoV-2 Vaccine
16%
Trained Immunity
16%
Bacillus Calmette
15%
Viral Infection
15%
Cellular Response
13%
Two-dose
13%
Inactivated Vaccine
13%
Systemic Lupus Erythematosus
13%
Cellular Immune Response
13%
Neutralizing Capacity
13%
Interferon-α (IFN-α)
13%
Humoral Immunity
12%
Mycobacterium Bovis
12%
Protective Immunity
12%
Immune Cells
12%
Interleukin-10
12%
Innate Immune Response
12%
Phase III Clinical Trial
12%
Variants of Concern
12%
Recombinant BCG Vaccine
12%
Surface Immunogenic Protein
12%
Group B Streptococcus
12%
Breakthrough Cases
12%
Second Dose
11%
Lung
11%
Mouse Model
11%
Nucleoprotein
11%
Pediatric Population
11%
Adaptive Immunity
11%
Clinical Trials
10%
Central Nervous System
10%
Humoral Response
10%
Immune System
10%
Autoimmune Response
10%
Viral Clearance
9%